The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
 
Andrew E. Sloan
Stock and Other Ownership Interests - Surgical Theater
Honoraria - Monteris Medical
Consulting or Advisory Role - Monteris Medical; Surgical Theater
Research Funding - Merck
Travel, Accommodations, Expenses - Monteris Medical
 
Robin Arthur Buerki
No Relationships to Disclose
 
Christopher Murphy
No Relationships to Disclose
 
Andrea True Kelly
Employment - Istari Oncology, Inc.
Leadership - SleepWorks (I)
 
Prakash Ambady
No Relationships to Disclose
 
Michael Brown
Employment - Avancen (I)
Patents, Royalties, Other Intellectual Property - ISTARI Oncology
 
Nicholas A. Butowski
Stock and Other Ownership Interests - Cordance; Cordance
Consulting or Advisory Role - Amgen; Cellinta; DelMar Pharmaceuticals; Karyopharm Therapeutics; KIYATEC; Lynx Group; Plus Therapeutics; QED Therapeutics; Tocagen; VBI Vaccines; VBL Therapeutics
Research Funding - Abbvie (Inst); Amgen; Amgen (Inst); Arbor Pharmaceuticals (Inst); BeiGene (Inst); BeiGene (Inst); BioMimetix (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EpicentRx; Five Prime Therapeutics; Ipsen; Istari (Inst); KIYATEC (Inst); Medicenna; Merck; Oncoceutics (Inst); Orbus Therapeutics; Tocagen (Inst)
 
Robert Cavaliere
Research Funding - ISTARI Oncology; Novocure; ZIOPHARM Oncology
 
William T. Curry
(OPTIONAL) Uncompensated Relationships - IMRIS
 
Annick Desjardins
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - Istari Oncology
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Orbus Therapeutics (Inst); Symphogen (Inst); Triphase Accelerator Corp (Inst)
Patents, Royalties, Other Intellectual Property - AU 2019247039 NEOADJUVANT CANCER TREATMENT; CA 2,892,183 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; Canada NEOADJUVANT CANCER TREATMENT; China NEOADJUVANT CANCER TREATMENT; EP 13856989.2 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; HK 15112399.5 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; JP 2020-554198 NEOADJUVANT CANCER TREATMENT; PCT/US2019/025402 NEOADJUVANT CANCER TREATMENT; South Korea 10-2020-7031272 NEOADJUVANT CANCER TREATMENT; US 15/428510 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; US 16/086,735 SEQUENTIAL ANTI-CANCER TREATMENT; US 16/505,771 ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS; US 17/016,699 ONCOLYTIC POLIOVIRUS FOR HUMAN TUMORS; US 17/044,645 NEOADJUVANT CANCER TREATMENT; US 62/651,470; US 62/823,277 NEOADJUVANT CANCER TREATMENT
 
Lisa Franklin
No Relationships to Disclose
 
Henry S. Friedman
Stock and Other Ownership Interests - Cancer Expert Now; Diverse Biotech; ISTARI Oncology
Consulting or Advisory Role - Cancer Expert Now; Diverse Biotech; ISTARI Oncology
Patents, Royalties, Other Intellectual Property - Letters of Patent for Oncolytic Poliovirus for Human Tumors
 
Matthias Gromeier
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - ISTARI Oncology
Research Funding - ISTARI Oncology
Patents, Royalties, Other Intellectual Property - ISTARI Oncology
Other Relationship - ISTARI Oncology
 
LeAnn Jackson
Employment - ISTARI Oncology
 
Lori Mixson
Stock and Other Ownership Interests - Merck
 
Shirley S. Ong
No Relationships to Disclose
 
Dina Randazzo
No Relationships to Disclose
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; deciphera; Deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Garrett Nichols
Employment - ISTARI Oncology
Leadership - Chimerix; ISTARI Oncology
Stock and Other Ownership Interests - Chimerix
Consulting or Advisory Role - Chimerix